Every Form 4 that Biogen Inc. (BIIB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BIIB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIIB filings page.
BIOGEN INC. (symbol: BIIB) is the issuer of record for a Form 4 filing submitted to the SEC. Parini Michael reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. (BIIB) reported that Chief Legal Officer Michael Parini received a grant of 7,405 Restricted Stock Units on September 1, 2026. The RSUs represent an equivalent number of shares of common stock and were awarded at a stated price of $0.00 per unit as an equity compensation award.
The RSUs vest in three equal yearly installments, beginning on the first anniversary of the grant date, September 1, 2026, and carry an expiration date of September 1, 2029. Following this grant, Parini holds 7,405 RSUs directly. No Rule 10b5-1 trading plan is reported for this award.
Biogen Inc. director Lloyd Minor reported selling a total of 1,186 shares of Biogen common stock in two open-market or private transactions. On 3 August 2026 he sold 593 shares at $203.34 per share, and on 4 August 2026 he sold 593 shares at $200.96 per share.
The trades involve non-derivative common stock held directly and are affirmed as having been executed under a Rule 10b5-1 trading plan.
BIOGEN INC. director William A. Hawkins reported an equity compensation award rather than an open-market trade. He acquired 1,505 shares of Common Stock at no cost under a grant classified as a “grant, award, or other acquisition.”
After this award, Hawkins directly holds 10,365 Common Stock shares. According to a footnote, the related restricted stock units vest on the earlier of the next annual meeting or the anniversary of the date of grant of June 9, 2026, tying this award to his ongoing board service.
SHERWIN STEPHEN A reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Stephen A. Sherwin reported receiving an equity award of 1,505 shares of common stock on June 9, 2026, at no cash cost to him, as a grant or award. Following this grant, he holds a total of 15,193 common shares directly.
The award consists of restricted stock units that will vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying the compensation to his continued board service over this period.
Rowinsky Eric K reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Eric K. Rowinsky received an equity grant as part of his compensation. He was awarded 1,505 shares of common stock in the form of restricted stock units at a grant price of $0.00 per share.
After this grant, he directly holds 25,844 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying his compensation to the company’s future performance over roughly a one-year period.
Mantas Jesus B reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Jesus B. Mantas reported an equity award of 1,505 shares of Common Stock, received as a grant rather than a market purchase. Following this award, his direct ownership increased to 11,263 shares.
The filing notes that the associated restricted stock units vest on the earlier of the company’s next annual meeting or the anniversary of the June 9, 2026 grant date, tying the award to continued board service over that period.
LANGER SUSAN reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Susan Langer received a grant of 1,505 shares of common stock as a compensation award. The grant was recorded at a price of $0.00 per share, indicating it was not an open-market purchase. After this award, she directly holds 6,634.1 common shares. A footnote explains that the restricted stock units from this grant vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying the award’s vesting to the company’s governance calendar.
Patolawala Monish D reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. director Monish D. Patolawala received an equity grant of 1,505 shares of Common Stock as a compensation award at no cost. Following this award, he directly holds 5,215 shares. The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date.
BIOGEN INC. director Menelas N. Pangalos reported routine equity compensation activity. He received a grant or award of 1,505 shares of Common Stock at a stated price of $0.00 per share, reflecting stock-based director compensation rather than an open-market purchase.
On the same date, he exercised 2,370 Restricted Stock Units into 2,370 shares of Common Stock, fully settling that RSU award. Following these transactions, his direct holdings of Biogen common stock increased to 3,875 shares. Footnotes state that the restricted stock units vest upon the earlier of the next annual meeting or the first anniversary of their respective grant dates.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Lloyd Minor received an equity award of 1,505 restricted stock units. These units were granted at no cash cost and increase his direct holdings to 3,875 shares of common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 grant anniversary.
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
Biogen director Maria C. Freire received an equity award of 2,005 shares of common stock in the form of restricted stock units. The grant carried no purchase price and represents compensation rather than an open-market trade. Following this award, she directly owns 8,820 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 anniversary of the grant date.
BIOGEN INC. Head of Corporate Development Adam Keeney reported routine equity compensation transactions involving the company’s common stock. On May 1, 2026, 939 restricted stock units were exercised into 939 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 455 shares of common stock were disposed of at a price of $187.06 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Keeney directly owned 6,365 shares of Biogen common stock. The restricted stock units that were exercised were part of an award that vests in three equal yearly installments beginning on the first anniversary of the May 1, 2023 grant date.
BIOGEN INC. Chief Accounting Officer Sean Godbout exercised 181 restricted stock units into 181 shares of common stock on April 1, 2026. The RSUs, granted on April 1, 2025, vest in three equal yearly installments, and this transaction reflects one vesting event.
To cover tax obligations, 54 shares of common stock were withheld at a price of $183.78 per share, leaving a net increase of 127 shares. Following these compensation-related transactions, Godbout directly holds about 1,341.6667 shares of Biogen common stock, indicating a routine equity vesting and tax-withholding pattern rather than open-market trading.
Viehbacher Christopher reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that President and CEO Christopher Viehbacher received a grant of 38,015 restricted stock units on February 13, 2026. These units are a form of equity compensation and were awarded at a stated price of $0.00 per unit.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. This means the award is structured to vest over three years, aligning the CEO’s compensation with longer-term company performance.
Singhal Priya reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Priya Singhal, Head of Development, received a grant of 10,560 restricted stock units. These RSUs were awarded at no cash cost per unit as part of equity compensation. According to the disclosure, the units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
BIOGEN INC. executive Nicole Murphy reported a grant of 10,560 restricted stock units and a small open-market share purchase. The restricted stock units were awarded on February 13, 2026 and vest in three equal yearly installments starting on the first anniversary of that grant date. On February 12, 2026 she bought 3 shares of Biogen common stock in an open-market transaction at a price of $195.035 per share. Following these transactions, her direct holdings total 19,611.0408 shares of common stock and 10,560 restricted stock units.
Biogen Inc. reported that Chief Financial Officer Robin Kramer acquired 8,450 restricted stock units as a grant on February 13, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting equity-based compensation rather than an open-market purchase.
According to the footnote, these restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. After this grant, Kramer directly holds 8,450 RSUs, which may convert into Biogen shares as they vest.
Keeney Adam reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. executive Adam Keeney, Head of Corporate Development, reported an award of 8,025 restricted stock units. These RSUs were granted at no purchase price and represent the right to receive Biogen common shares upon vesting. The units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
Izzar Rachid reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Rachid Izzar, Head of Global Product Strategy, received a grant of 7,390 restricted stock units. These RSUs were awarded at no cash cost per unit and represent a form of stock-based compensation that aligns the executive’s interests with shareholders.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. The entire 7,390-unit award is reported as directly owned following the transaction.
Grogan Jane reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Head of Research Jane Grogan received a grant of 8,450 restricted stock units (RSUs) on February 13, 2026. These RSUs vest in three equal yearly installments, beginning on the first anniversary of the grant date, providing her with long-term, equity-based compensation rather than an open-market share purchase or sale.
Gregory Ginger reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Gregory Ginger, EVP of Human Resources, received an equity grant of 8,025 restricted stock units on February 13, 2026. These RSUs were awarded at no cash cost to him as part of his compensation and represent a right to receive Biogen shares in the future.
The 8,025 restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. All units are reported as directly owned following the grant, meaning his reported derivative holdings increased by the full award amount.
Godbout Sean reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. Chief Accounting Officer Sean Godbout reported receiving a grant of 1,800 restricted stock units. These RSUs were awarded at a stated price of $0.00 per unit and increase his directly owned derivative holdings to 1,800 units. According to the footnote, the award vests in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026, meaning one-third of the units will vest each year over a three-year period.
ALEXANDER SUSAN H reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that EVP and Chief Legal Officer Susan H. Alexander received a grant of 8,450 restricted stock units on February 13, 2026. These units represent a form of equity compensation rather than a cash transaction. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date, meaning the award is earned over time as continued service is provided.
Biogen Inc. President and CEO Christopher Viehbacher reported multiple equity transactions on February 6, 2026 as restricted stock units converted into common shares and a portion of the new shares was withheld for taxes.
He acquired 9,008 and 15,453 shares of Biogen common stock at an exercise price of $0 through the vesting and settlement of previously granted restricted stock units. To satisfy tax obligations tied to these vestings, 4,356 shares and 6,624 shares were automatically withheld at a price of $201.18 per share. After these transactions, he directly owned 29,924 shares of common stock, along with 9,009 and 30,907 restricted stock units that continue to vest in three equal annual installments from their respective 2024 and 2025 grant dates.
Biogen Inc.’s Head of Development, Priya Singhal, reported multiple equity transactions in early February 2026. On February 6, 2026, she exercised restricted stock units into 2,217 and 4,683 shares of common stock at an exercise price of $0 per share. To cover associated obligations, 1,056 and 1,412 shares of common stock were withheld at $201.18 per share. On February 9, 2026, she sold 2,660 common shares at $199.83 per share, leaving 8,043.1428 common shares owned directly and 9,367 restricted stock units outstanding that vest in three annual installments from 2024 and 2025 grant dates.
Biogen Inc. executive Nicole Murphy, Head of Pharm Ops and Tech, reported multiple equity transactions dated 02/06/2026. Several tranches of restricted stock units converted into common stock, including 2,102, 1,940 and 4,683 units, each at an exercise price of $0.
To cover related tax obligations, common shares were withheld at $201.18 per share in amounts of 1,017, 914 and 1,408 shares. Following these transactions, Murphy directly beneficially owned 19,608.0408 shares of Biogen common stock, which includes 166.6667 shares acquired under the Biogen employee stock purchase plan on 3/31/2025.
Biogen Inc. Chief Financial Officer Robin Kramer reported several stock transactions dated February 6, 2026 related to vesting of restricted stock units (RSUs). RSU awards for 789, 703 and 3,511 units were converted into an equal number of Biogen common shares at an exercise price of $0.
To cover tax obligations on these vestings, Kramer had 273, 207 and 1,063 Biogen common shares withheld or disposed of at a transaction price of $201.18 per share. After these transactions, Kramer directly beneficially owned 11,471.7483 shares of Biogen common stock and continued to hold RSUs that vest in three equal annual installments under prior grants.
Biogen Inc. Head of Corporate Development Adam Keeney reported multiple equity transactions dated February 6, 2026. He acquired 1,802 and 3,278 shares of common stock at $0 per share through the exercise of restricted stock units, then disposed of 589 and 994 shares at $201.18 per share.
Following these transactions, Keeney directly beneficially owned 5,881 shares of Biogen common stock and 6,557 restricted stock units. The restricted stock units referenced in the filing vest in three equal annual installments starting one year after their respective grant dates in 2024 and 2025.
Biogen officer Rachid Izzar, Head of Global Product Strategy, reported multiple transactions on common stock tied to vested restricted stock units on February 6, 2026. Several RSU awards were exercised at an exercise price of $0 per share and converted into Biogen common stock.
In connection with these vestings, shares were automatically withheld at $201.18 per share to cover tax obligations, rather than sold on the open market. After these transactions, Izzar directly owned 11,011 shares of Biogen common stock. Footnotes explain that the underlying RSU grants vest in three equal annual installments starting one year after grant dates in 2023, 2024, and 2025.
Biogen Inc. Head of Research Jane Grogan reported equity compensation activity on February 6, 2026. She converted 1,385 and 1,873 restricted stock units into common stock at an exercise price of $0 per share and had shares withheld to cover taxes at $201.18 per share.
After these transactions, she directly owned 4,058 shares of Biogen common stock and 3,747 restricted stock units. One RSU grant vests in three equal annual installments starting one year after the February 7, 2024 grant date, and another vests in three yearly installments beginning on the first anniversary of the February 6, 2025 grant date.
Biogen Inc. executive Ginger Gregory, EVP of Human Resources, reported multiple equity award transactions dated 02/06/2026. The filing shows restricted stock units converting into common stock at an exercise price of $0 and related dispositions of common shares at $201.18 per share.
Individual conversions include 1,635, 1,802, and 3,746 restricted stock units, each linked to previously granted awards scheduled to vest in three equal annual installments beginning one year after their respective grant dates in 2023, 2024, and 2025. Following these transactions, Gregory directly holds 22,358.7673 shares of Biogen common stock and 7,494 restricted stock units.
Biogen Inc. (BIIB) Chief Accounting Officer Sean Godbout reported multiple equity compensation transactions dated February 6, 2026. Restricted stock units for 257, 305, and 517 shares were converted (code M) into common stock at an exercise price of $0 per share.
On the same date, he disposed of 76, 103, and 180 common shares (code F) at $201.18 per share. Following these transactions, Godbout directly owned 1,214.6667 shares of Biogen common stock.
Biogen Inc. executive Susan H. Alexander, EVP Chief Legal Officer, reported multiple equity transactions on 02/06/2026. Several restricted stock unit awards were exercised, delivering 2,190, 1,940 and 4,916 shares of Biogen common stock at an exercise price of $0.
In related transactions, 1,059, 931 and 1,514 shares of common stock were withheld at a price of $201.18 per share, typically reflecting shares retained to cover tax obligations. After these transactions, she directly held 41,807 shares of Biogen common stock and indirectly held 20,082 shares through the Susan H. Alexander 2021 Irrevocable Trust.
Biogen Inc.’s Head of Development, Priya Singhal, reported equity transactions involving company stock. On January 30, 2026, 1,829 shares of common stock were acquired at $0 following the vesting and exercise of a restricted stock unit award granted on February 1, 2023 that vests in three equal annual installments.
Also on January 30, 2026, 582 shares were surrendered at $179.89, and on February 2, 2026, 748 shares were sold at $179.3. After these transactions, Singhal directly held 6,271.1428 shares of Biogen common stock.
Biogen Inc. President and CEO Christopher A. Viehbacher reported equity transactions in the company’s common stock. On December 1, 2025, 7,040 shares of common stock were acquired at a price of $0 per share through the exercise of previously granted restricted stock units, coded as transaction type M. On the same date, 3,404 shares of common stock were disposed of in a transaction coded F at a price of $177.78 per share. After these transactions, Viehbacher beneficially owned 16,443 shares of Biogen common stock directly. The underlying restricted stock unit award, originally granted on December 1, 2022, vested on its third anniversary and represented one share of common stock for each unit.
Biogen Inc. (BIIB) reported insider equity activity by its Head of Research. On 10/31/2025, 695 shares of common stock were acquired at $0 under a transaction coded M, reflecting settlement of previously granted RSUs. A separate transaction coded F covered 337 shares at $154.27. Following these transactions, the officer directly owned 1,791 shares of common stock.
The derivative table shows 695 restricted stock units outstanding after the activity, tied to an award granted on 11/01/2023 that vests in three equal annual installments beginning on 11/01/2024, with an expiration date of 11/01/2026.
Sean Godbout, identified as a Director and the issuer's Chief Accounting Officer, reported changes in his beneficial ownership of BioGen Inc. (BIIB) on 10/02/2025. He had restricted stock units (RSUs) vest that resulted in an acquisition of 502.6667 shares at no cash cost (code M), and on the same date he disposed of 8 shares by sale at $155.25 (code F), leaving him with 494.6667 shares reported as beneficially owned. The RSUs were granted on 10/02/2023 and vest in three equal annual installments beginning one year after the grant date; the filing was signed by an attorney-in-fact on 10/06/2025.